Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 663-676
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Table 1 Baseline characteristics
Parameter | Number of participants (n = 66) |
Mean age (yr) | 53.3 ± 13.6 |
Sex | |
Male | 55 |
Female | 11 |
Maximum tumor diameter (cm) | |
≤ 5 | 27 |
5-10 | 26 |
> 10 | 13 |
Child-Pugh score | |
A | 57 |
B7 | 9 |
BCLC stage | |
B | 29 |
C | 37 |
ECOG PS | |
0 | 46 |
1 | 20 |
Vascular invasion | |
Present | 25 |
Absent | 41 |
Portal vein invasion | |
Present | 23 |
Absent | 43 |
Extrahepatic metastasis | |
Present | 16 |
Absent | 50 |
HBV | |
Positive | 54 |
Negative | 12 |
HBV DNA (copies/mL) | |
> 2 × 103 | 30 |
≤ 2 × 103 | 36 |
Cirrhosis | |
Present | 50 |
Absent | 16 |
AFP (ng/mL) | |
≤ 100 | 26 |
> 100 | 40 |
- Citation: Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
- URL: https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.663